Participants in the study will receive either the medication Enpatoran or a placebo, which looks like the medication but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will be conducted over a long period, allowing researchers to gather information on how well the medication is tolerated and any side effects that may occur.

Throughout the study, participants will be monitored for any adverse events, which are unexpected medical problems that occur during treatment. The study will also look at any changes in laboratory tests and heart function, specifically the QT interval, which is a measure of the heart’s electrical activity. This information will help determine the safety profile of Enpatoran for people with lupus. Participants who successfully complete the initial part of the study may have the opportunity to continue in a long-term extension of the study to gather more data on the medication’s effects.

The purpose of this study is to investigate how anifrolumab affects inflammatory cells, which are cells involved in the body’s immune response, in the skin and blood of people with cutaneous lupus erythematosus. The study will examine changes in these cells and how genes are expressed, meaning how active certain genes are in these cells. Additionally, the study will look at how the medication affects the clinical course of the disease, which refers to how the symptoms and overall condition progress over time.

During the study, participants will receive anifrolumab through infusion, which means the medication will be given directly into a vein over a period of time. The maximum daily dose is 300 milligrams, and participants may receive up to 3900 milligrams in total over the treatment period of 48 weeks. Skin and blood samples will be collected and analyzed using various laboratory techniques to understand how the inflammatory cells change during treatment. The study will also monitor how the skin condition responds to the treatment.

The purpose of this study is to find out if lenalidomide is better than methotrexate at improving active skin lesions after sixteen weeks of treatment. During the study, participants will continue taking their medication for several months while doctors regularly check their skin condition using a scoring system that measures how active and severe the skin lesions are. The doctors will look at whether the skin lesions have decreased by at least half compared to the start of the study. Participants may also continue using their current medications such as antimalarials, low-dose steroids, or creams if their doses have been stable before joining the study.

Throughout the study, doctors will also measure other aspects of the condition, including how much the skin lesions improve at different time points, changes in quality of life, and whether the broader lupus condition becomes more or less active. The study will track any side effects that occur during treatment and follow-up periods. Women who can become pregnant will need to use effective birth control methods and have monthly pregnancy tests, as these medications can cause harm to an unborn baby. The study will continue for several years to gather enough information about how well these treatments work and how safe they are for people with difficult-to-treat skin lupus.

The purpose of this research is to determine how well VENT-03 works in reducing the severity of skin symptoms in adults with active cutaneous lupus. During the study, participants will receive either VENT-03 tablets or placebo tablets that look identical but contain no active medication. After the initial phase where neither participants nor doctors know who receives which treatment, the study continues with an open-label extension where all participants receive the active medication.

The study will measure how the skin symptoms change over time, particularly focusing on the improvement in skin lesions. Throughout the study, participants will undergo various health assessments to monitor their response to treatment and ensure their safety. The medication’s levels in the blood will also be measured to understand how the body processes it.

The purpose of the study is to evaluate how well IMVT-1402 works in improving the condition of participants with CLE. Participants will receive either the treatment or a placebo, and the study will monitor changes in their skin condition over time. The trial will last for up to 52 weeks, during which participants will have regular check-ups to assess their response to the treatment.

Throughout the study, the main focus will be on the safety and tolerability of IMVT-1402, as well as its effectiveness in reducing the severity of skin symptoms associated with CLE. The study aims to provide valuable information on whether IMVT-1402 can be a beneficial treatment option for individuals living with this skin condition.

The purpose of the study is to assess the effectiveness and safety of Anifrolumab in improving skin conditions associated with Cutaneous Lupus Erythematosus. Participants will receive either Anifrolumab or a placebo through a subcutaneous injection, which means the injection is given under the skin. The study will be conducted in two stages, with the main focus on observing changes in skin symptoms at Week 24. The study will last up to 52 weeks, allowing researchers to monitor the long-term effects of the treatment.

Throughout the study, participants will be closely monitored for any changes in their skin condition and any side effects they may experience. The study aims to provide valuable information on whether Anifrolumab can be a beneficial treatment option for those with Cutaneous Lupus Erythematosus who have limited options due to their intolerance or inadequate response to existing therapies.

Participants in the study will receive either the BIIB059 injection or a placebo, which looks like the treatment but does not contain the active ingredient. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will take place over a period of time, with regular check-ups to monitor the participants’ health and the effects of the treatment.

The trial is divided into two parts, and participants will be assessed using specific scores that measure the severity and activity of their skin condition. These scores help researchers understand how well the treatment is working. The study aims to provide valuable information about the potential benefits of BIIB059 for people with these challenging skin conditions. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.

The purpose of this research is to evaluate how different doses of enpatoran work in reducing disease activity, particularly focusing on skin symptoms and overall disease control. During the study, participants will receive either enpatoran tablets or placebo in addition to their current lupus medications. The study will track changes in participants’ symptoms and overall health for up to 24 months.

This is a Phase 2 study, which means the medication has already been tested for basic safety in humans, and researchers are now studying how well it works at different doses. The study is designed to be double-blind, which means neither the participants nor the healthcare providers will know who is receiving enpatoran or placebo during the study period.

During the study, participants will take the medication for a period of up to 12 weeks. Throughout this time, they will have regular check-ups to monitor their health and the effects of the treatment. The study will look at changes in the severity of the skin condition and any side effects that may occur. The goal is to see if GS-5718 can help reduce the symptoms of CLE and improve the quality of life for those affected by this condition.

Participants will be closely monitored for any adverse effects, and the study will also gather information on how the body processes the medication. This research is important for understanding whether GS-5718 can be a beneficial treatment option for people living with Cutaneous Lupus Erythematosus.

The purpose of the study is to see how well PF-06823859 works in reducing the activity of lupus in the skin. Participants will be randomly assigned to receive either the treatment or the placebo. The study will last for several weeks, during which participants will receive the treatment through an injection into a vein, known as intravenous administration. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment.

By the end of the study, researchers hope to understand more about the safety and effectiveness of PF-06823859 in treating skin symptoms of lupus. This information could help in developing better treatments for people with CLE and SLE in the future.

Participants in the study will receive the BIIB059 treatment over a period of time, and their health will be monitored to see how they respond to the medication. The study will look at how well the treatment works in reducing the severity of the skin conditions and any potential side effects that may occur. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

The study will last for up to 128 weeks, during which participants will have regular check-ups to assess their condition and any changes in their symptoms. The goal is to gather information on how safe and effective BIIB059 is for treating these types of lupus-related skin conditions over a long period. This information will help determine if the treatment can be a viable option for people with these conditions in the future.

The purpose of the study is to evaluate how well deucravacitinib works in reducing the severity of skin symptoms in participants with active DLE and/or SCLE. Participants will be randomly assigned to receive either the medication or a placebo. The study will last for a period of up to 52 weeks, during which participants will have regular check-ups to monitor their condition and any changes in their symptoms. The main focus will be on the change in the severity of skin symptoms at Week 16, as measured by a specific scoring system used to assess skin disease activity.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The study aims to provide valuable information on the potential benefits and risks of using deucravacitinib for treating these specific types of lupus. This research could contribute to better understanding and management of DLE and SCLE, potentially offering new treatment options for those affected by these conditions.